Promethera Biosciences

Promethera Biosciences

Promethera Biosciences is a biotechnology company developing regenerative medicine treatments for liver diseases.

Promethera Biosciences is a biotechnology company developing regenerative medicine treatments for liver diseases that is headquartered in Mont-Saint-Guibert, Belgium and was founded in 2009 by Etienne Sokal.

The company is a spin-off of the Universita Catholique de Louvain, and is interested in developing treatments based on allogenic adult stem cell technology. They look to commercialize cell therapy products to treat liver diseases using progenitor cells from healthy human livers. The progenitor cells that Promethera Biosciences are adult liver-derived mesenchymal progenitor cells.

Promethera Biosciences looks to develop new cell and antibody-based therapies for the treatment of liver diseases. The company has developed a cell-based therapy called HepaStem, which has potential to provide novel treatment options for chronic and acute live diseases. This could be successful for Acute-on-Chronic Liver Failure, fibrosis, and non-alcoholic SteatoHepatitis. The HepaStem can be administered intravenously, transported through the bloodstream to the liver, and provide it a chance to repair and regenerate. It reduces inflammation processes as well as fibrogenesis, as it inhibits hepatic stellate cell activation and collagen secretion, and degrades the excessive extracellular matrix.

Another product of Promethera Biosciences is the H2Stem. The H2Stem is used to display a high capacity for homing, in situ differentiation into hepatocytes and repopulation after their transplantation in a model of human xenografts.

The company's third and fourth product are the antibody-based drug candidates which includes the Atrosab and Atrosimab. These products target the pro-inflammatory tumor necrosis factor receptor 1, and blocks its activation by TNF-alpha without interacting with the TNF receptor 2.

Timeline

May 6, 2019
Promethera Biosciences raises a $44,400,000 series D round from ITOCHU Corporation.
March 28, 2012
Promethera Biosciences raises a $31,475,320 series B round from Boehringer Ingelheim, Belgian Sambrinvest, Shire, Mitsui Global Investment and Atmi.
February 2, 2010
Promethera Biosciences raises a $7,300,000 series A round.
2009
Promethera Biosciences was founded by Etienne Sokal.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Promethera Biosciences Series B round
31,475,320
March 28, 2012
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Bertrand Lellouche

CFO EU / US Financial Operations

Etienne Sokal

Founder, Chief Scientific & Medical Officer

Henrik L. Luessen

Chief Business Officer

Jef Pinxteren

VP Operations

John Tchelingerian

President & CEO

Mark Johnston

MBA, CCO Promethera Biosciences Group (Belgium) & Managing Director of Promethera Bisociences LLC (USA)

Mutsuki Takano

Group Chief Financial Officer , Branch General Manager of Promethera Biosciences Japan Branch

Nathalie Belmonte

VP Product Development

Paul Smith

VP Regulatory Affairs

Further reading

Title
Author
Link
Type
Date

cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada

Business Wire

Web

Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad Strategic Collaboration to Access the Asian Markets

Business Wire

Web

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

JULIE LELLOUCHE

Web

Promethera Biosciences Raised Additional EUR 9.3 Million to Advance a Broad Product Pipeline in Severe Liver Diseases

Business Wire

Web

Documentaries, videos and podcasts

Title
Date
Link

Promethera BioSciences

October 24, 2016

Promethera Biosciences official channel

January 24, 2019

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.